Scott H Kaufmann

List of Publications by Year
in descending order

336	28,461	5558 82	6113 159
papers	citations	h-index	g-index

434	434	434	29223
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Manifold medicine: A schema that expands treatment dimensionality. Drug Discovery Today, 2022, 27, 8-16.	3.2	5
2	Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. Cancer Research, 2022, 82, 1038-1054.	0.4	26
3	Therapeutics targeting BCL2 family proteins. , 2022, , 197-260.		3
4	Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2022, 82, 307-319.	0.4	8
5	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic Oncology, 2022, 164, 245-253.	0.6	15
6	Uncovering Pharmacological Opportunities for Cancer Stem Cellsâ€"A Systems Biology View. Frontiers in Cell and Developmental Biology, 2022, 10, 752326.	1.8	9
7	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 721-735.	1.1	5
8	Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors. Translational Oncology, 2022, 21, 101427.	1.7	1
9	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	2.9	21
10	Circulating CD14 + HLAâ€ÐR lo/â^' monocytic cells as a biomarker for epithelial ovarian cancer progression. American Journal of Reproductive Immunology, 2021, 85, e13343.	1.2	4
11	CDK2-Mediated Upregulation of TNFÎ± as a Mechanism of Selective Cytotoxicity in Acute Leukemia. Cancer Research, 2021, 81, 2666-2678.	0.4	5
12	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€“ A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	1.2	8
13	USP13 regulates the replication stress response by deubiquitinating TopBP1. DNA Repair, 2021, 100, 103063.	1.3	10
14	Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. Journal of Physical Education and Sports Management, 2021, 7, a006083.	0.5	5
15	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Scientific Reports, 2021, 11, 8076.	1.6	9
16	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	5.8	116
17	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	5.8	44
18	The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches. Genes, 2021, 12, 1098.	1.0	9

#	Article	IF	Citations
19	Porphyromonas somerae Invasion of Endometrial Cancer Cells. Frontiers in Microbiology, 2021, 12, 674835.	1.5	7
20	Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	1.6	20
21	Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2021, 81, 4709-4722.	0.4	42
22	PARP inhibitor maintenance for primary ovarian cancer â€“ A missed opportunity for precision medicine. Gynecologic Oncology, 2021, 163, 11-13.	0.6	7
23	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death and Disease, 2021, 12, 789.	2.7	4
24	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 490-497.	0.6	20
25	Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. , 2021, 4, 125-142.		26
26	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease, 2021, 12, 977.	2.7	33
27	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology, 2021, 7, 1772.	3.4	44
28	TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia. Blood Cancer Discovery, 2021, 2, 162-185.	2.6	22
29	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers, 2021, 13, 6043.	1.7	0
30	A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML). Blood, 2021, 138, 2347-2347.	0.6	1
31	Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Reports Medicine, 2021, 2, 100471.	3.3	26
32	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 2021, 13, 6385.	1.7	19
33	Therapeutic options for mucinous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 552-560.	0.6	49
34	Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2. PLoS Pathogens, 2020, 16, e1008906.	2.1	25
35	Selective Inhibition of BFL1: Itâ€™s All about Finding the Right Partner. Cell Chemical Biology, 2020, 27, 639-642.	2.5	2
36	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43

#	Article	IF	Citations
37	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	2.9	35
38	FAM111A protects replication forks from protein obstacles via its trypsin-like domain. Nature Communications, 2020, 11, 1318.	5.8	67
39	Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer. Cancer Research, 2020, 80, 857-867.	0.4	33
40	Characterization of an alternative BAK-binding site for BH3 peptides. Nature Communications, 2020, 11, 3301.	5.8	31
41	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. Clinical Cancer Research, 2020, 26, 3397-3407.	3.2	45
42	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor Î±. Clinical Cancer Research, 2020, 26, 2986-2996.	3.2	17
43	Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation. Blood, 2020, 136, 12-13.	0.6	0
44	BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Research, 2019, 79, 5920-5929.	0.4	40
45	ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nature Communications, 2019, 10, 4632.	5.8	21
46	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
47	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.	0.6	56
48	Genes associated with bowel metastases in ovarian cancer. Gynecologic Oncology, 2019, 154, 495-504.	0.6	40
49	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
50	Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Scientific Reports, 2019, 9, 3617.	1.6	9
51	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	5.1	191
52	A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational New Drugs, 2019, 37, 307-314.	1.2	5
53	BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	7.7	278
54	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American Journal of Hematology, 2019, 94, 111-117.	2.0	21

#	Article	IF	Citations
55	A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML). Blood, 2019, 134, 3837-3837.	0.6	3
56	Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. F1000Research, 2019, 8, 1704.	0.8	42
57	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. Blood, 2019, 134, 1710-1710.	0.6	0
58	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochemical Pharmacology, 2018, 152, 279-292.	2.0	35
59	Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. Journal of Hepatology, 2018, 68, 1228-1238.	1.8	17
60	Measurement of BH3-only protein tolerance. Cell Death and Differentiation, 2018, 25, 282-293.	5.0	27
61	A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clinical Cancer Research, 2018, 24, 744-752.	3.2	43
62	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	5.8	192
63	Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metabolism, 2018, 28, 833-847.e8.	7.2	46
64	Gadolinium-enhanced cardiac MR exams of human subjects are associated with significant increases in the DNA repair marker 53BP1, but not the damage marker Î³H2AX. PLoS ONE, 2018, 13, e0190890.	1.1	4
65	Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis. Nucleic Acids Research, 2017, 45, 4564-4576.	6.5	91
66	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 75-87.	5.1	975
67	Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	7.7	310
68	Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition. Journal of Virology, 2017, 91, .	1.5	54
69	Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. Clinical Cancer Research, 2017, 23, 4077-4085.	3.2	80
70	Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research, 2017, 61, 108-116.	0.4	41
71	Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. Stem Cells Translational Medicine, 2017, 6, 840-850.	1.6	5
72	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 697-706.	3.2	56

#	Article	IF	Citations
73	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clinical Cancer Research, 2017, 23, 899-907.	3.2	37
74	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget, 2017, 8, 94569-94579.	0.8	4
75	Getting a GRP on histone deacetylase inhibitor selectivity. Oncotarget, 2017, 8, 78249-78250.	0.8	0
76	Mitochondrial apoptosis and BH3 mimetics. F1000Research, 2016, 5, 2804.	0.8	33
77	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clinical Cancer Research, 2016, 22, 3894-3902.	3.2	23
78	Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes. Organic and Biomolecular Chemistry, 2016, 14, 4103-4109.	1.5	3
79	4EBP1/c-MYC/PUMA and NF-Î²B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood, 2016, 127, 2711-2722.	0.6	49
80	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology, 2016, 143, 379-388.	0.6	57
81	Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Research, 2016, 44, 2816-2826.	6.5	42
82	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2016, 22, 4746-4755.	3.2	59
83	Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. Journal of Virology, 2016, 90, 4032-4048.	1.5	85
84	Somatic Mosaic Mutations inPPM1DandTP53in the Blood of Women With Ovarian Carcinoma. JAMA Oncology, 2016, 2, 370.	3.4	88
85	A cell cycle-dependent BRCA1â€“UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nature Communications, 2016, 7, 10201.	5.8	95
86	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. Journal of Clinical Oncology, 2016, 34, 5540-5540.	0.8	25
87	Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.. , 2016, , .		0
88	Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.. , 2016, , .		0
89	Abstract A07: Homologous recombination mutations and overall survival in high-grade serous, endometrioid, and clear cell ovarian carcinomas.. , 2016, , .		0
90	Abstract 1260: Polymerase kappa determines the sensitivity of MTH1 inhibitors to cisplatin-resistant cell. , 2016, , .		0

#	Article	IF	Citations
91	Abstract 3292: Manipulating osteoblast differentiation in order to inhibit protection of AML cells within the bone marrow. , 2016, , .		0
92	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood, 2015, 125, 658-667.	0.6	108
93	COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A. Molecular Biology of the Cell, 2015, 26, 91-103.	0.9	200
94	Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9860-9865.	3.3	3
95	TP53mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Research, 2015, 43, 6945-6958.	6.5	46
96	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1658-1671.	1.9	122
97	Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. Journal of Clinical Oncology, 2015, 33, 1397-1406.	0.8	295
98	Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1Î±-TAZ Signaling Pathway in Osteoblasts. Journal of Biological Chemistry, 2015, 290, 29478-29492.	1.6	18
99	Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes and Development, 2015, 29, 2140-2152.	2.7	38
100	Abstract 3479: CPX-351 (cytarabine:daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition. , 2015, , .		1
101	Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia. Blood, 2015, 126, 2563-2563.	0.6	2
102	mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies. Blood, 2015, 126, 3705-3705.	0.6	0
103	MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia. Blood, 2015, 126, 1273-1273.	0.6	8
104	Evaluation of the BH3-only Protein Puma as a Direct Bak Activator. Journal of Biological Chemistry, 2014, 289, 89-99.	1.6	65
105	Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica, 2014, 99, 60-69.	1.7	26
106	Chk1 and WEE1 Inhibition Combine Synergistically and Represent a Novel Non-cytotoxic Combination in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S127-S128.	0.2	0
107	Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. International Journal of Cancer, 2014, 135, 1783-1789.	2.3	13
108	Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons. Molecular Pharmacology, 2014, 85, 723-734.	1.0	6

#	Article	IF	Citations
109	Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1288-1297.	3.2	168
110	Osteoblasts Protect AML Cells From SDFâ€1â€Induced Apoptosis. Journal of Cellular Biochemistry, 2014, 115, 1128-1137.	1.2	32
111	Auxin-induced Rapid Degradation of Inhibitor of Caspase-activated DNase (ICAD) Induces Apoptotic DNA Fragmentation, Caspase Activation, and Cell Death. Journal of Biological Chemistry, 2014, 289, 31617-31623.	1.6	26
112	Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. Journal of Cell Biology, 2014, 206, 867-876.	2.3	28
113	Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression. Journal of Biological Chemistry, 2014, 289, 20543-20558.	1.6	47
114	Molecular correlates of platinum response in human highâ€grade serous ovarian cancer patientâ€derived xenografts. Molecular Oncology, 2014, 8, 656-668.	2.1	117
115	Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis. Journal of Biological Chemistry, 2014, 289, 22835-22849.	1.6	47
116	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. Journal of Clinical Oncology, 2014, 32, TPS5619-TPS5619.	0.8	8
117	Abstract CT339: Prospective molecular identification of ovarian cancer patients benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy - reaching beyond germline BRCA mutations. , 2014, , .		0
118	Abstract 38: Using molecularly characterized patient-derived models to delineate underlying drivers and vulnerabilities of epithelial ovarian cancer. , 2014, , .		0
119	Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs, 2013, 31, 1201-1206.	1.2	19
120	Comparison of complication rates of Hickman^{Â®}catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leukemia and Lymphoma, 2013, 54, 1263-1267.	0.6	29
121	CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of the Bcl-2 Family Members Bcl-XL, Noxa, and Bak. Journal of Biological Chemistry, 2013, 288, 22899-22914.	1.6	59
122	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. Cancer Research, 2013, 73, 7222-7231.	0.4	153
123	ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status. Cancer Research, 2013, 73, 3683-3691.	0.4	160
124	The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Frontiers in Oncology, 2013, 3, 228.	1.3	95
125	Contribution of Bcl-2 Phosphorylation to Bak Binding and Drug Resistance. Cancer Research, 2013, 73, 6998-7008.	0.4	81
126	Abstract 1737: Pharmacological inhibition of fatty acid synthase regulates BH3-only proteins and sensitizes breast cancer cells to a small molecule Bcl-2/Bcl-xL inhibitor to induce apoptosis.. , 2013, , .		0

#	Article	IF	Citations
127	Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer. , 2013, , .		1
128	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000.	0.6	0
129	Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. Clinical Cancer Research, 2012, 18, 6723-6731.	3.2	100
130	Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro. Clinical Cancer Research, 2012, 18, 5364-5373.	3.2	53
131	Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors: Figure 1.. Genes and Development, 2012, 26, 305-311.	2.7	77
132	Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro. Clinical Cancer Research, 2012, 18, 1655-1662.	3.2	204
133	Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. Scientific Reports, 2012, 2, 257.	1.6	41
134	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood, 2012, 119, 476-487.	0.6	91
135	Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood, 2012, 119, 55-63.	0.6	23
136	Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes. Journal of Biological Chemistry, 2012, 287, 4198-4210.	1.6	89
137	How does doxorubicin work?. ELife, 2012, 1, e00387.	2.8	64
138	Therapyâ€related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy*. European Journal of Haematology, 2012, 88, 237-243.	1.1	25
139	A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecologic Oncology, 2012, 124, 210-215.	0.6	23
140	Abstract 4179: Loss of Hsulf-1 promotes chemoresistance and tumorigenecity in ovarian cancer. , 2012, , .		0
141	Abstract 3276: A novel in vivo xenograft mouse model of human high-grade serous ovarian cancer, with clinical, molecular and functional annotation relevant for pre-clinical analysis. , 2012, , .		0
142	Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio. Blood, 2012, 120, 1508-1508.	0.6	1
143	A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer. Cancer Investigation, 2011, 29, 617-625.	0.6	10
144	High Cell Surface Death Receptor Expression Determines Type I Versus Type II Signaling*. Journal of Biological Chemistry, 2011, 286, 35823-35833.	1.6	27

#	Article	IF	Citations
145	Death Receptor 5 Signaling Promotes Hepatocyte Lipoapoptosis. Journal of Biological Chemistry, 2011, 286, 39336-39348.	1.6	106
146	Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica, 2011, 96, 1619-1626.	1.7	37
147	Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood, 2011, 118, 4872-4881.	0.6	27
148	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood, 2011, 118, 4882-4889.	0.6	37
149	Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2011, 67, 455-463.	1.1	18
150	Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells. Cancer Research, 2011, 71, 4944-4954.	0.4	42
151	Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. Journal of Cell Biology, 2011, 194, 39-48.	2.3	139
152	Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3406-3411.	3.3	475
153	Isolation of a TRAIL Antagonist from the Serum of HIV-infected Patients*. Journal of Biological Chemistry, 2011, 286, 35742-35754.	1.6	16
154	Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells. Journal of Biological Chemistry, 2011, 286, 17682-17692.	1.6	80
155	Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia. Blood, 2011, 118, 1531-1531.	0.6	2
156	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,. Blood, 2011, 118, 3634-3634.	0.6	6
157	Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders. Blood, 2011, 118, 400-400.	0.6	5
158	Abstract 1301: Investigation of a potential pharmacokinetic interaction between ABT-888 and topotecan in a phase I trial. , 2011, , .		0
159	PARP inhibition: PARP1 and beyond. Nature Reviews Cancer, 2010, 10, 293-301.	12.8	1,166
160	Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals, 2010, 3, 1311-1334.	1.7	50
161	Protein Kinase CÎ² Modulates Ligand-induced Cell Surface Death Receptor Accumulation. Journal of Biological Chemistry, 2010, 285, 888-902.	1.6	15
162	Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition. Hepatology Research, 2010, 40, 701-710.	1.8	7

#	Article	IF	Citations
163	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. Blood, 2010, 116, 287-287.	0.6	5
164	Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association. Blood, 2010, 116, 772-772.	0.6	11
165	OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy. Blood, 2010, 116, 970-970.	0.6	1
166	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias. Blood, 2010, 116, 3276-3276.	0.6	0
167	Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro. Cancer Research, 2009, 69, 7635-7643.	0.4	53
168	Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis. Journal of Biological Chemistry, 2009, 284, 18311-18322.	1.6	47
169	Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. Molecular Cancer Therapeutics, 2009, 8, 855-863.	1.9	23
170	Mcl-1 Degradation during Hepatocyte Lipoapoptosis. Journal of Biological Chemistry, 2009, 284, 30039-30048.	1.6	37
171	On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4459-4462.	1.0	13
172	The Nitric Acid Method for Protein Estimation in Biological Samples. Springer Protocols, 2009, , 35-45.	0.1	0
173	Reutilization of Western Blots After Chemiluminescent or Autoradiographic Detection. Springer Protocols, 2009, , 789-806.	0.1	0
174	Death Receptor 5 Internalization Is Required for Lysosomal Permeabilization by TRAIL in Malignant Liver Cell Lines. Gastroenterology, 2009, 136, 2365-2376.e7.	0.6	68
175	Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood, 2009, 113, 4841-4852.	0.6	54
176	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood, 2009, 114, 2926-2935.	0.6	152
177	Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. Journal of Clinical Investigation, 2009, 119, 2714-24.	3.9	24
178	Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines.. Blood, 2009, 114, 2742-2742.	0.6	0
179	Lowâ€dose, singleâ€agent temsirolimus for relapsed mantle cell lymphoma. Cancer, 2008, 113, 508-514.	2.0	220
180	Dynamics of granzyme B-induced apoptosis: Mathematical modeling. Mathematical Biosciences, 2008, 212, 54-68.	0.9	4

#	Article	IF	Citations
181	Apoptosis-associated caspase activation assays. Methods, 2008, 44, 262-272.	1.9	76
182	Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines. Molecular Pharmacology, 2008, 74, 724-735.	1.0	8
183	BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Molecular Cancer Therapeutics, 2008, 7, 2339-2347.	1.9	38
184	Mitotic Phosphorylation Stimulates DNA Relaxation Activity of Human Topoisomerase I. Journal of Biological Chemistry, 2008, 283, 16711-16722.	1.6	15
185	Anticancer therapy: boosting the bang of Bim. Journal of Clinical Investigation, 2008, 118, 3582-3584.	3.9	18
186	Serine 64 Phosphorylation Enhances the Antiapoptotic Function of Mcl-1. Journal of Biological Chemistry, 2007, 282, 18407-18417.	1.6	94
187	Tumor Necrosis Factor-related Apoptosis-inducing Ligand Activates a Lysosomal Pathway of Apoptosis That Is Regulated by Bcl-2 Proteins. Journal of Biological Chemistry, 2007, 282, 28960-28970.	1.6	113
188	Genetic Analysis of the Short Splice Variant of the Inhibitor of Caspase-activated DNase (ICAD-S) in Chicken DT40 Cells. Journal of Biological Chemistry, 2007, 282, 27374-27382.	1.6	12
189	MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis. Journal of Biological Chemistry, 2007, 282, 29831-29846.	1.6	104
190	A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 2007, 109, 1387-1394.	0.6	180
191	The Intrinsic Pathway of Apoptosis. , 2007, , 3-30.		3
192	Altered Apoptosis in AML. , 2007, , 133-161.		1
193	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics, 2006, 5, 2378-2387.	1.9	102
194	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood, 2006, 107, 2501-2506.	0.6	76
195	Synthesis of Novel Caspase Inhibitors for Characterization of the Active Caspase Proteome in Vitro and in Vivo. Journal of Medicinal Chemistry, 2006, 49, 7636-7645.	2.9	9
196	Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Current Treatment Options in Oncology, 2006, 7, 285-294.	1.3	70
197	Apoptosis in the treatment of cancer: a promise kept?. Current Opinion in Cell Biology, 2006, 18, 668-676.	2.6	65
198	Imatinib spells BAD news for Bcr/abl-positive leukemias. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14651-14652.	3.3	9

#	Article	IF	Citations
199	Genetic analysis of apoptotic execution. Sub-Cellular Biochemistry, 2006, 40, 75-90.	1.0	1
200	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. Journal of Clinical Investigation, 2006, 116, 1994-2004.	3.9	130
201	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. Blood, 2006, 108, 530-530.	0.6	6
202	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood, 2005, 105, 2099-2106.	0.6	40
203	Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood, 2005, 106, 318-327.	0.6	118
204	Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene, 2005, 24, 5089-5100.	2.6	57
205	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 2005, 24, 6861-6869.	2.6	254
206	Cell division, growth and death. Current Opinion in Cell Biology, 2005, 17, 565-567.	2.6	1
207	Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. American Journal of Hematology, 2005, 79, 119-127.	2.0	3
208	Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia. Clinical Cancer Research, 2005, 11, 6641-6649.	3.2	26
209	The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons. Journal of Biological Chemistry, 2005, 280, 14349-14355.	1.6	92
210	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 5347-5356.	0.8	509
211	Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points. Clinical Cancer Research, 2005, 11, 5935-5941.	3.2	65
212	Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-Î²-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias. Clinical Cancer Research, 2005, 11, 8403-8412.	3.2	84
213	Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidine (SCH66336). Molecular Pharmacology, 2005, 68, 477-486.	1.0	11
214	Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival. Molecular Pharmacology, 2005, 68, 1636-1644.	1.0	119
215	Interleukin-6 Contributes to Mcl-1 Up-regulation and TRAIL Resistance via an Akt-Signaling Pathway in Cholangiocarcinoma Cells. Gastroenterology, 2005, 128, 2054-2065.	0.6	204
216	Approaches Used to Detect Apoptosis. , 2005, , 35-54.		0

#	Article	IF	Citations
217	Genomic Mechanisms of p210BCR-ABL Signaling. Journal of Biological Chemistry, 2004, 279, 35604-35615.	1.6	47
218	Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death. Journal of Biological Chemistry, 2004, 279, 18641-18647.	1.6	37
219	Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells. Cancer Research, 2004, 64, 3517-3524.	0.4	204
220	Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel. Clinical Cancer Research, 2004, 10, 6807-6820.	3.2	61
221	Caspase-7 Gene Disruption Reveals an Involvement of the Enzyme during the Early Stages of Apoptosis. Journal of Biological Chemistry, 2004, 279, 1030-1039.	1.6	38
222	A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene, 2004, 23, 1636-1644.	2.6	157
223	Apoptosis: an optimization approach. Computers in Biology and Medicine, 2004, 34, 449-459.	3.9	5
224	Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin. Leukemia and Lymphoma, 2004, 45, 1545-1551.	0.6	57
225	Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood, 2004, 103, 3271-3277.	0.6	163
226	Hopes for kinase inhibitors active against AML take FLT. Blood, 2004, 103, 8-8.	0.6	0
227	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.. Blood, 2004, 104, 129-129.	0.6	6
228	Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.. Blood, 2004, 104, 2097-2097.	0.6	2
229	S-peptide epitope tagging for protein purification, expression monitoring, and localization in mammalian cells. BioTechniques, 2004, 37, 835-9.	0.8	38
230	Irinotecan in the treatment of glioma patients. Cancer, 2003, 97, 2352-2358.	2.0	36
231	Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 2003, 22, 7414-7430.	2.6	253
232	Imatinib mesylate (STI-571), a c-Abl kinase inhibitor, indirectly blocks receptor tyrosine kinase activation and induces apoptosis in a human cholangiocarcinoma cell line. Gastroenterology, 2003, 124, A742.	0.6	0
233	Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro. Journal of Biological Chemistry, 2003, 278, 47326-47339.	1.6	52
234	Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 1760-1766.	0.8	200

#	Article	IF	Citations
235	Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood, 2003, 102, 4512-4519.	0.6	66
236	Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer. Journal of Biological Chemistry, 2003, 278, 23107-23117.	1.6	215
237	Heterogeneous Role of Caspase-8 in Fenretinide-Induced Apoptosis in Epithelial Ovarian Carcinoma Cell Lines. Molecular Pharmacology, 2003, 64, 1434-1443.	1.0	23
238	A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clinical Cancer Research, 2003, 9, 2520-6.	3.2	40
239	Lack of Correlation between Caspase Activation and Caspase Activity Assays in Paclitaxel-treated MCF-7 Breast Cancer Cells. Journal of Biological Chemistry, 2002, 277, 804-815.	1.6	64
240	Phorbol 12-myristate 13-Acetate Inhibits Death Receptor-mediated Apoptosis in Jurkat Cells by Disrupting Recruitment of Fas-associated Polypeptide with Death Domain. Journal of Biological Chemistry, 2002, 277, 3776-3783.	1.6	72
241	Reutilization of Western Blots After Chemiluminescent Detection or Autoradiography. , 2002, , 439-452.		1
242	Calpain-mediated X-linked Inhibitor of Apoptosis Degradation in Neutrophil Apoptosis and Its Impairment in Chronic Neutrophilic Leukemia. Journal of Biological Chemistry, 2002, 277, 33968-33977.	1.6	96
243	Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ. Journal of Biological Chemistry, 2002, 277, 44236-44243.	1.6	239
244	The Nitric Acid Method for Protein Estimation in Biological Samples. , 2002, , 31-40.		0
245	Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood, 2002, 99, 664-671.	0.6	107
246	S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function. Journal of Biological Chemistry, 2002, 277, 1599-1606.	1.6	179
247	Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology, 2002, 122, 985-993.	0.6	166
248	Neutropenic Colitis After Treatment of Acute Myelogenous Leukemia With Idarubicin and Cytosine Arabinoside. Mayo Clinic Proceedings, 2002, 77, 760-762.	1.4	32
249	G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells. Journal of Clinical Investigation, 2002, 110, 91-99.	3.9	173
250	A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Investigational New Drugs, 2002, 20, 297-304.	1.2	5
251	Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO Journal, 2002, 21, 1967-1977.	3.5	233
252	Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Research, 2002, 62, 6500-5.	0.4	72

#	Article	IF	Citations
253	Analysis of Caspase Activation During Apoptosis. Current Protocols in Cell Biology, 2001, 11, Unit 18.2.	2.3	7
254	A Multistep Model for Paclitaxel-Induced Apoptosis in Human Breast Cancer Cell Lines. Experimental Cell Research, 2001, 270, 277-288.	1.2	81
255	Caspases 3 and 9 Send a Pro-Apoptotic Signal from Synapse to Cell Body in Olfactory Receptor Neurons. Journal of Neuroscience, 2001, 21, 7099-7109.	1.7	114
256	Apoptosis and the response to anticancer therapy. Current Opinion in Oncology, 2001, 13, 453-462.	1.1	79
257	Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 2001, 97, 3361-3369.	0.6	445
258	Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT388â€“granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. Blood, 2001, 98, 1927-1934.	0.6	19
259	Current status of clinical trials of farnesyltransferase inhibitors. Current Opinion in Oncology, 2001, 13, 470-476.	1.1	93
260	Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells. Chromosoma, 2001, 110, 65-74.	1.0	104
261	Reutilization of Immunoblots after Chemiluminescent Detection. Analytical Biochemistry, 2001, 296, 283-286.	1.1	62
262	Is TRAIL hepatotoxic?. Hepatology, 2001, 34, 3-6.	3.6	77
263	Programmed cell death: alive and well in the new millennium. Trends in Cell Biology, 2001, 11, 526-534.	3.6	603
264	Is TRAIL hepatotoxic?. Hepatology, 2001, 34, 3-6.	3.6	43
265	Apoptosis in cancer: cause and cure. BioEssays, 2000, 22, 1007-1017.	1.2	181
266	Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood, 2000, 96, 3922-3931.	0.6	54
267	Effect of 6-Aminonicotinamide and Other Protein Synthesis Inhibitors on Formation of Platinum-DNA Adducts and Cisplatin Sensitivity. Molecular Pharmacology, 2000, 57, 529-538.	1.0	24
268	Retention of the Human Rad9 Checkpoint Complex in Extraction-resistant Nuclear Complexes after DNA Damage. Journal of Biological Chemistry, 2000, 275, 26343-26348.	1.6	99
269	Induction of Apoptosis by Cancer Chemotherapy. Experimental Cell Research, 2000, 256, 42-49.	1.2	1,101
270	Detection of DNA Cleavage in Apoptotic Cells. Methods in Enzymology, 2000, 322, 3-15.	0.4	50

#	Article	IF	Citations
271	Successful Virtual Screening of a Chemical Database for Farnesyltransferase Inhibitor Leads. Journal of Medicinal Chemistry, 2000, 43, 401-408.	2.9	130
272	Nitric oxide (NO) inhibits apoptosis in cholangiocarcinoma cells by blocking caspase 9 activation. Gastroenterology, 2000, 118, A962.	0.6	0
273	Cathepsin B contributes to TNF-Î±â€“mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. Journal of Clinical Investigation, 2000, 106, 1127-1137.	3.9	635
274	Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood, 2000, 96, 3922-3931.	0.6	5
275	Immunoblot Analysis and Band Depletion Assays. , 1999, 94, 253-268.		16
276	Characterization of Caspase Processing and Activation in HL-60 Cell Cytosol Under Cell-free Conditions. Journal of Biological Chemistry, 1999, 274, 22635-22645.	1.6	63
277	Caspase-mediated Cleavage of DNA Topoisomerase I at Unconventional Sites during Apoptosis. Journal of Biological Chemistry, 1999, 274, 4335-4340.	1.6	94
278	Comparison of Paclitaxel-, 5-Fluoro-2â€²-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis. Journal of Biological Chemistry, 1999, 274, 15927-15936.	1.6	79
279	Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis. Annual Review of Biochemistry, 1999, 68, 383-424.	5.0	2,499
280	A One-Step Method for Protein Estimation in Biological Samples: Nitration of Tyrosine in Nitric Acid. Analytical Biochemistry, 1999, 267, 217-221.	1.1	28
281	Hypercalcemia Complicating Leukemic Transformation of Agnogenic Myeloid Metaplasia-Myelofibrosis. Mayo Clinic Proceedings, 1999, 74, 1233-1237.	1.4	13
282	Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochemical Pharmacology, 1999, 58, 1057-1066.	2.0	23
283	Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. Journal of Clinical Investigation, 1999, 103, 137-145.	3.9	485
284	Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody. Molecular and Cellular Biochemistry, 1998, 178, 245-249.	1.4	8
285	Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 195-211.	2.4	239
286	Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemotherapy and Pharmacology, 1998, 42, 391-399.	1.1	66
287	Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cellsâ˜†â˜†â˜†. Gastroenterology, 1998, 114, 930-939.	0.6	80
288	Topoisomerase II and the Response to Antileukemic Therapy. Leukemia and Lymphoma, 1998, 29, 217-237.	0.6	20

#	Article	IF	Citations
289	Transition from Caspase-dependent to Caspase-independent Mechanisms at the Onset of Apoptotic Execution. Journal of Cell Biology, 1998, 143, 225-239.	2.3	122
290	Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis. Blood, 1998, 92, 3042-3049.	0.6	48
291	Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. Blood, 1998, 91, 991-1000.	0.6	263
292	Erasure of Western Blots After Autoradiographic or Chemiluminescent Detection. Methods in Molecular Biology, 1998, 80, 223-235.	0.4	12
293	Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. Blood, 1998, 91, 991-1000.	0.6	265
294	Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis. Blood, 1998, 92, 3042-3049.	0.6	13
295	The Role of Proteases in Neuronal Apoptosis. Frontiers in Neuroscience, 1998, , .	0.0	3
296	Methods Used to Study Protease Activation During Apoptosis. Frontiers in Neuroscience, 1998, , .	0.0	1
297	Activation of Multiple Interleukin-1Î² Converting Enzyme Homologues in Cytosol and Nuclei of HL-60 Cells during Etoposide-induced Apoptosis. Journal of Biological Chemistry, 1997, 272, 7421-7430.	1.6	197
298	Chemotherapy-Induced Apoptosis. Advances in Pharmacology, 1997, 41, 461-499.	1.2	126
299	Methods Utilized in the Study of Apoptosis. Advances in Pharmacology, 1997, 41, 57-87.	1.2	43
300	Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis. Blood, 1997, 90, 4283-4296.	0.6	119
301	Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells. Blood, 1997, 89, 2098-2104.	0.6	51
302	Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions. Blood, 1997, 90, 935-943.	0.6	247
303	Caspases and caspase inhibitors. Trends in Biochemical Sciences, 1997, 22, 388-393.	3.7	517
304	Resistance to topoisomerase II poisons: Is the answer in the promoter?. Leukemia Research, 1997, 21, 1033-1036.	0.4	1
305	Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. , 1997, 71, 817-824.		50
306	Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis. Blood, 1997, 90, 4283-4296.	0.6	27

#	Article	IF	Citations
307	Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions. Blood, 1997, 90, 935-943.	0.6	72
308	Factors Affecting Topotecan Sensitivity in Human Leukemia Samples. Annals of the New York Academy of Sciences, 1996, 803, 128-142.	1.8	11
309	Proteolytic cleavage during chemotherapy-induced apoptosis. Trends in Molecular Medicine, 1996, 2, 298-303.	2.6	30
310	Alteration of the Nucleolar Localization of Poly(ADP-ribose) Polymerase upon Treatment with Transcription Inhibitors. Experimental Cell Research, 1996, 227, 146-153.	1.2	61
311	The role of proteases during apoptosis. FASEB Journal, 1996, 10, 587-597.	0.2	538
312	Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines. Journal of the National Cancer Institute, 1996, 88, 734-741.	3.0	153
313	Addition of Etoposide to Initial Therapy of Adult Acute Lymphoblastic Leukemia: A Combined Clinicaland Laboratory Study. Leukemia and Lymphoma, 1996, 23, 71-83.	0.6	14
314	Detection of Poly(ADP-Ribose) Polymerase and Its Apoptosis-Specific Fragment by a Nonisotopic Activityâ€“Western Blot Technique. Analytical Biochemistry, 1995, 232, 251-254.	1.1	47
315	Evaluation of 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl) hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistancein vitro. Investigational New Drugs, 1995, 13, 285-294.	1.2	8
316	Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Biochemical Pharmacology, 1995, 50, 1987-1993.	2.0	6
317	Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemotherapy and Pharmacology, 1994, 34, S53-S57.	1.1	32
318	Topoisomerases in Human Leukemia. Advances in Pharmacology, 1994, 29B, 33-50.	1.2	3
319	Erasure of Western blots after autoradiography or chemiluminescent detection. Applied Biochemistry and Biotechnology, 1993, 38, 243-255.	1.4	2
320	The Current Status of Camptothecin Analogues as Antitumor Agents. Journal of the National Cancer Institute, 1993, 85, 271-291.	3.0	574
321	Erasable Western Blots. , 1992, 80, 235-246.		3
322	Proteolytic Cleavage of Poly(ADP-Ribose) Polymerase in Human Leukemia Cells Treated with Etoposide and other Cytotoxic Agents. , 1992, , 260-268.		1
323	Association of topoisomerase II with the hepatoma cell nuclear matrix: The role of intermolecular disulfide bond formation. Experimental Cell Research, 1991, 192, 511-523.	1.2	57
324	Association of poly(ADP-ribose) polymerase with the nuclear matrix: The role intermolecular disulfide bond formation, RNA retention, and cell type. Experimental Cell Research, 1991, 192, 524-535.	1.2	56

#	Article	IF	Citations
325	Severe Graft-versus-Host Disease in a Liver-Transplant Recipient. New England Journal of Medicine, 1988, 318, 689-691.	13.9	174
326	The erasable Western blot. Analytical Biochemistry, 1987, 161, 89-95.	1.1	172
327	Analysis of the internal nuclear matrix. Experimental Cell Research, 1986, 164, 139-153.	1.2	61
328	A subset of non-histone nuclear proteins reversibly stabilized by the sulfhydryl cross-linking reagent tetrathionate. Experimental Cell Research, 1984, 155, 477-495.	1.2	152
329	Binding of dexamethasone to rat liver nuclei in vivo and in vitro: Evidence for two distinct binding sites. The Journal of Steroid Biochemistry, 1984, 20, 699-708.	1.3	27
330	An Alternative Approach to the Quantitation of Glucocorticoid-Receptor Complexes in the Nuclei of Lymphoid Cells*. Endocrinology, 1982, 110, 708-716.	1.4	15
331	Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Experimental Cell Research, 1981, 132, 105-123.	1.2	270
332	Increased phosphorylation rate of intermediate filaments during mitotic arrest. Experimental Cell Research, 1981, 133, 445-449.	1.2	21
333	The relationship of the nuclear matrix to cellular structure and function. Advances in Enzyme Regulation, 1979, 17, 213-248.	2.9	103
334	Apoptotic Pathways in Cancer Progression and Treatment. , 0, , 143-170.		1
335	Targeting the Apoptotic Machinery as a Potential Antileukemic Strategy. , 0, , 163-186.		1
336	Erasure of Western Blots After Autoradiographic or Chemiluminescent Detection. , 0, , 223-236.		0